Safety under the regulatory spotlight — 140 documents in 90 days

6 documents in the last 30 days alone

This concentration of safety-related publications may indicate a tightening regulatory cycle, or at minimum a period of heightened scrutiny around risk management, signal detection, and post-market surveillance. Sponsors should consider that regulators may be emphasizing faster responses to emerging safety issues, more explicit benefit-risk justification, and closer alignment between clinical, pharmacovigilance, and labeling strategies. Companies with safety programs should be watching for shifts in adverse event reporting expectations, class-wide safety signals, and any guidance that could affect how quickly they need to update risk mitigation plans or safety narratives.